This article is free to access.
Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment. © 2012 Färnert et al.; licensee BioMed Central Ltd.
Färnert, A., Ursing, J., Tolfvenstam, T., Rono, J., Karlsson, L., Sparrelid, E., & Lindegårdh, N. (2012). Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania. Malaria Journal, 11. https://doi.org/10.1186/1475-2875-11-176
Mendeley helps you to discover research relevant for your work.